You are here: Industry Insights > Johnson & Johnson

News List

AdoRx Therapeutics Announces Collaboration with Johnson & Johnson americanpharmaceuticalreview
March 01, 2019
AdoRx Therapeutics has entered into a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to develop novel therapeutics for the treatment of lung cancer.
U.S. Agencies Probing Johnson & Johnson Over Asbestos in Talc drugs
February 22, 2019
Johnson & Johnson is being investigated by the U.S. Justice Department and the U.S. Securities and Exchange Commission over possible asbestos contamination of the company's baby powder and other talc-based products....
Johnson & Johnson to Acquire Auris Health americanpharmaceuticalreview
February 15, 2019
Johnson & Johnson announced that Ethicon entered into a definitive agreement to acquire Auris Health for approximately $3.4 billion in cash....
Johnson & Johnson to disclose drug prices in television ads pharmaceutical-technology
February 13, 2019
Johnson & Johnson has announced plans to disclose the price of its prescription medicines directly to customers on TV advertisements in a bid to improve transparency.....
Philogen Announces Drug Discovery Collaboration With Johnson & Johnson Innovation pharmafocusasia
January 25, 2019
Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc. ....
Discounting hit J&J's Xarelto hard. Can a new launch turn things around? fiercepharma
January 23, 2019
Competition and discounting are understandably plaguing Johnson & Johnson's older drugs. But its cardiovascular blockbuster Xarelto is also on that list.
Johnson & Johnson's fourth-quarter drug sales rise 5.3 percent, led by Stelara, Imbruvica, Darzalex firstwordpharma
January 22, 2019
Credit Suisse analyst Vamil Divan noted that Johnson & Johnson's quarterly profit was boosted by from an effective tax rate of 2.6 percent, amounting to just $80 million. Meanwhile, J.P. Morgan analyst Chris Schott said the positive outlook for the compan
Johnson & Johnson's fourth-quarter drug sales rise 5.3 percent, led by Stelara, Imbruvica, Darzalex firstwordpharma
January 22, 2019
Credit Suisse analyst Vamil Divan noted that Johnson & Johnson's quarterly profit was boosted by from an effective tax rate of 2.6 percent, amounting to just $80 million. Meanwhile, J.P. Morgan analyst Chris Schott said the positive outlook for the compan
Johnson & Johnson, AbbVie superstar Imbruvica flunks pancreatic cancer test fiercepharma
January 22, 2019
AbbVie and Johnson & Johnson’s blockbuster Imbruvica is approved to treat six diseases, but it looks like pancreatic cancer won’t be its seventh.
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis fiercepharma
January 13, 2019
Johnson & Johnson knows the immunology market is crowded. But that doesn’t mean it doesn’t still see tons of opportunity there.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page